Cargando…

Cytoreductive surgery is feasible in patients with limited regional platinum-resistant recurrent ovarian cancer

INTRODUCTION: To evaluate the efficacy of cytoreductive surgery versus chemotherapy for the treatment of limited regional, platinum-resistant ovarian cancer (PROC). MATERIALS AND METHODS: The clinical records of all patients with PROC treated in our center between March 2015 and March 2022 were retr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zou, Ruoyao, Jiang, Qidi, Luo, Xukai, Chen, Mo, Yuan, Lei, Yao, Liangqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688147/ https://www.ncbi.nlm.nih.gov/pubmed/38037085 http://dx.doi.org/10.1186/s12957-023-03230-3

Ejemplares similares

A durable response to programmed cell death 1 blockade in a multidrug-resistant recurrent ovarian cancer patient with HLA-B44 supertype: A case report
por: Luo, Xukai, et al.
Publicado: (2022)

Pan-cancer analyses and molecular subtypes based on the cancer-associated fibroblast landscape and tumor microenvironment infiltration characterization reveal clinical outcome and immunotherapy response in epithelial ovarian cancer
por: Zou, Ruoyao, et al.
Publicado: (2022)

Secondary cytoreduction surgery improves prognosis in platinum-sensitive recurrent ovarian cancer
por: Xu, Xia, et al.
Publicado: (2013)

Update on the secondary cytoreduction in platinum-sensitive recurrent ovarian cancer: a narrative review
por: Conte, Carmine, et al.
Publicado: (2021)

Novel prognostic nomograms to assess survival in high-grade serous ovarian carcinoma after surgery and chemotherapy: a retrospective cohort study from SEER database
por: Huang, Wu, et al.
Publicado: (2022)

Feasibility of laparoscopic cytoreduction in patients with localized recurrent epithelial ovarian cancer
por: Paik, E Sun, et al.
Publicado: (2016)

Platinum resistant recurrence and early recurrence in a multi-centre cohort of patients undergoing interval cytoreductive surgery for advanced epithelial ovarian cancer
por: Bhatt, Aditi, et al.
Publicado: (2022)

The role of secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer: what do the trials tell us?
por: Coleman, Robert L.
Publicado: (2020)

Blocking CD47-SIRPα Signal Axis as Promising Immunotherapy in Ovarian Cancer
por: Luo, Xukai, et al.
Publicado: (2023)

The current role of secondary cytoreductive surgery for recurrent ovarian cancer
por: de Bree, Eelco, et al.
Publicado: (2022)

Ovarian Carcinosarcoma: Effects of Cytoreductive Status and Platinum-Based Chemotherapy on Survival
por: Jernigan, Amelia M., et al.
Publicado: (2013)

Do ethnic chinese older adults with epithelial ovarian cancer survive a poorer prognosis?
por: Huang, Wu, et al.
Publicado: (2023)

Cytoreductive surgery in ovarian cancer
por: Pomel, Christophe, et al.
Publicado: (2007)

Simplified Selection Criteria for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer
por: Son, Joo-Hyuk, et al.
Publicado: (2022)

The value of PET/CT for cytoreductive surgery selection in recurrent ovarian carcinoma
por: Nunes, Rafael Leite, et al.
Publicado: (2023)

Artificial intelligence weights the importance of factors predicting complete cytoreduction at secondary cytoreductive surgery for recurrent ovarian cancer
por: Bogani, Giorgio, et al.
Publicado: (2018)

Laparoscopic splenectomy both for primary cytoreductive surgery for advanced ovarian cancer and for secondary surgery for isolated spleen recurrence: feasibility and technique
por: Macciò, Antonio, et al.
Publicado: (2021)

Robotic-assisted interval cytoreductive surgery in ovarian cancer: a feasibility study
por: Carbajal-Mamani, Semiramis L., et al.
Publicado: (2020)

Phase 2 non-randomised trial of secondary cytoreduction and hyperthermic intraperitoneal chemotherapy in recurrent platinum-sensitive ovarian cancer
por: Raj, Hemanth, et al.
Publicado: (2021)

Role of HIPEC after Complete Cytoreductive Surgery (CRS) in Peritoneal Recurrence of Platinum-Sensitive Recurrent Ovarian Cancer (OC): The Aim for Standardization at Two Reference Centers for CRS
por: Acs, Miklos, et al.
Publicado: (2023)

A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study
por: Shi, Tingyan, et al.
Publicado: (2020)

Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patients selection
por: Onda, T, et al.
Publicado: (2005)

Which patients benefit from secondary cytoreductive surgery in recurrent ovarian cancer?
por: Zang, Rongyu, et al.
Publicado: (2019)

Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial
por: Qi, Yuwen, et al.
Publicado: (2022)

Surgery in platinum-resistant recurrent epithelial ovarian carcinoma
por: Zhao, Ling-Qin, et al.
Publicado: (2022)

Tertiary cytoreduction in the setting of recurrent ovarian cancer (Review)
por: DOGAN, NASUH UTKU, et al.
Publicado: (2013)

Minimally-Invasive Secondary Cytoreduction in Recurrent Ovarian Cancer
por: Certelli, Camilla, et al.
Publicado: (2023)

Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study
por: Petrillo, Marco, et al.
Publicado: (2019)

Addendum: A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study
por: Shi, Tingyan, et al.
Publicado: (2022)

Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience
por: Tuninetti, Valentina, et al.
Publicado: (2020)

Prediction Models for Complete Resection in Secondary Cytoreductive Surgery of Patients With Recurrent Ovarian Cancer
por: Jiang, Caixia, et al.
Publicado: (2021)

Morbidity and mortality in women with advanced ovarian cancer who underwent primary cytoreductive surgery compared to cytoreductive surgery for recurrent disease: a meta-analysis
por: Bartels, Helena C., et al.
Publicado: (2019)

Investigating the effect of optimal cytoreduction in the context of platinum sensitivity in high‐grade serous ovarian cancer
por: Cardillo, Nicholas, et al.
Publicado: (2022)

Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study
por: van de Laar, Rafli, et al.
Publicado: (2014)

Comments on: Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study
por: Batista, Thales Paulo, et al.
Publicado: (2019)

A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses
por: Bogani, Giorgio, et al.
Publicado: (2018)

Hepatic Hilar Lymph Node Resection in Cytoreductive Surgery for Advanced Ovarian Cancer: A Necessity or Not?
por: Huang, Honglian, et al.
Publicado: (2021)

Splenectomy during cytoreductive surgery in epithelial ovarian cancer
por: Sun, Hengzi, et al.
Publicado: (2018)

Liver Resection as Part of Cytoreductive Surgery for Ovarian Cancer
por: Luna-Abanto, Jorge, et al.
Publicado: (2020)

Significance of cholecystectomy in cytoreductive surgery for advanced ovarian cancer
por: Son, Joo-Hyuk, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9ljpmcdhqdjapjpf3t73rr17mi